Navigation Links
Watson Reaches Settlement with Teva Over Seasonale(R)
Date:5/7/2010

MORRISTOWN, N.J., May 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Teva Women's Health, Inc. on outstanding patent litigation related to Teva's Seasonale® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg) product.

On December 13, 2007, Teva filed a patent infringement lawsuit against Watson in the United States District Court for the District of New Jersey involving Watson's Quasense® product, which is a generic equivalent of Teva's Seasonale®.  Under terms of the settlement agreement, Teva has granted Watson a fully paid-up license to the U.S. patents covering Seasonale® and Watson will continue marketing its generic equivalent product Quasense® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg).  Watson further admits that the licensed patents are valid and enforceable.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance.  Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business.  These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report for the year ended December 31,2009.  Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms EVISTA(R) Patent Challenge
2. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 7th
3. Watson To Present at Bank Of America/Merrill Lynch 2010 Healthcare Conference
4. Watson Confirms Trilipix(R) Patent Challenge
5. Watson Confirms Rapamune(R) Patent Challenge
6. Watson Confirms Cenestin(R) Patent Challenge
7. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
8. Watson to Present at Barclays 2010 Global Healthcare Conference
9. Watson Receives FDA Approval for Generic Cardizem(R) LA
10. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
11. Watson Announces Actos(R) Patent Challenge Settlement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2017)... Aug. 29, 2017 In a move that ... regulatory compliance for veterinary practices of all sizes, Cubex ... partnership that makes TITAN,s expertise in physical security, drug ... Cubex,s clients nationally. ... handling controlled substances is at risk today," said TITAN ...
(Date:8/28/2017)... 28, 2017   Aesculight ®, a division of LightScalpel ®, ... lasers. Built on over 20 years of American veterinary laser surgery innovation, ... Exclusive VetScalpel®Features and Enhancements ... is excising a tumor with his new VetScalpel laser. Dr. Duclos practices ... ...
(Date:8/25/2017)... 25, 2017   West Pharmaceutical Services, Inc. (NYSE: ... administration, announced that management will be presenting a West business ... Management will present at the Baird 2017 ... New York, N.Y. , at 3:10 p.m. ... Conference, at the Westin Boston Waterfront in Boston, ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... 20, 2017 , ... “Psalms of Humidity”: is a fascinating depiction of daily ... readers one step closer to God. “Psalms of Humidity” is the creation of published ... been made within his life are the very same things that have shaped him ...
(Date:9/20/2017)... ... 2017 , ... “The Financial Favor of God; Second Edition”: a personal and ... is the creation of published author, Brooks Rathell. , “We typically hear about the ... about the financial favor of God. Not only does it exist, but it is ...
(Date:9/20/2017)... ... , ... “Monique”: is the story of Monique, whose mother’s deteriorating physical ... author, Colleen Crispi, has owned four beauty salons and written a book regarding the ... and cooking. , “The doctor’s office was only three blocks away, and she ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians were selected ... own Ross A. Clevens, MD, FACS . The founder and medical director of ... Reconstructive Surgeon who trained at Yale, Harvard and the University of Michigan. He has ...
(Date:9/19/2017)... Alabama (PRWEB) , ... September 19, 2017 , ... ... customer success story on St. Vincent’s Infusion Services called, “PAPA Healthcare helps fill ... St. Vincent’s Infusion Services enhanced service delivery and operations by leveraging PAPA Healthcare’s ...
Breaking Medicine News(10 mins):